News|Articles|March 5, 2019

FDA Commissioner Scott Gottlieb, MD, Resigns

The FDA commissioner plans to leave the agency in April.

FDA Commissioner Scott Gottlieb, MD, has resigned, according to reports from the Washington Postand a statement from Health and Human Services (HHS) Secretary, Alex Azar. The resignation will be effective in a month, according to HHS.

“All of us at HHS are proud of the remarkable work Commissioner Gottlieb has done at the FDA. He has been an exemplary public health leader, aggressive advocate for American patients, and passionate promoter of innovation. I will personally miss working with Scott on the important goals we share, and I know that is true for so many other members of the HHS family,” Azar said in a March 5, 2019 statement. “Scott’s leadership inspired historic results from the FDA team, which delivered record approvals of both innovative treatments and affordable generic drugs, while advancing important policies to confront opioid addiction, tobacco and youth e-cigarette use, chronic disease, and more. The public health of our country is better off for the work Scott and the entire FDA team have done over the last two years.”

The Washington Post is reporting that the resignation was not at the request of the White House, and was a surprise some FDA officials.

Source: Washington Post, HHS

 


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.